CD30/TNFRSF8 Antibody [ADC] - (Brentuximab Vedotin, Research Grade)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-44512
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
ADC
Antibody Source
Monoclonal Human IgG1
Concentration
LYOPH mg/ml
Product Specifications
Immunogen
CD30/TNFRSF8 (Uniprot: P28908)
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Theoretical MW
145.48 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Description
This product is an Antibody-Drug Conjugate (ADC) for Research Use Only (RUO).
Brentuximab vedotin is an ADC consisting of a CD30-directed antibody and Monomethyl auristatin E (MMAE) that inhibits CD30-positive cells and is used for the study of relapsed and refractory Hogkin's lymphoma.
This product is shipped at ambient temperature. Upon receipt, store immediately at -20C or lower for 12 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
Brentuximab vedotin is an ADC consisting of a CD30-directed antibody and Monomethyl auristatin E (MMAE) that inhibits CD30-positive cells and is used for the study of relapsed and refractory Hogkin's lymphoma.
This product is shipped at ambient temperature. Upon receipt, store immediately at -20C or lower for 12 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
Scientific Data Images for CD30/TNFRSF8 Antibody [ADC] - (Brentuximab Vedotin, Research Grade)
![Hu CD30/TNFRSF8 mAb [ADC] - (Brentuximab Vedotin)](https://resources.bio-techne.com/images/products/nbp3-44512_human-cd30-tnfrsf8-brentuximab-vedotin-mab-28220258111612.png "ELISA: Hu CD30/TNFRSF8 mAb [ADC] - (Brentuximab Vedotin) [NBP3-44512] -")
ELISA: Hu CD30/TNFRSF8 mAb [ADC] - (Brentuximab Vedotin) [NBP3-44512] -
ELISA: CD30/TNFRSF8 (Brentuximab Vedotin) Antibody [NBP3-44512] - Immobilized human CD30 His at 2 ug/mL can bind CD30/TNFRSF8 (Brentuximab Vedotin) Antibody, EC50=0.006007 ug/mL.Applications for CD30/TNFRSF8 Antibody [ADC] - (Brentuximab Vedotin, Research Grade)
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Spectra Viewer
Plan Your Experiments
Use our spectra viewer to interactively plan your experiments, assessing multiplexing options. View the excitation and emission spectra for our fluorescent dye range and other commonly used dyes.
Spectra Viewer
Formulation, Preparation, and Storage
Purification
> 90% by SDS-PAGE and HPLC
Reconstitution
Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.
Formulation
Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
Preservative
No Preservative
Concentration
LYOPH mg/ml
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C in powder form. Store at -80C once reconstituted.
Background: CD30/TNFRSF8
Alternate Names
CD30, TNFRSF8
Additional CD30/TNFRSF8 Products
Product Documents for CD30/TNFRSF8 Antibody [ADC] - (Brentuximab Vedotin, Research Grade)
Product Specific Notices for CD30/TNFRSF8 Antibody [ADC] - (Brentuximab Vedotin, Research Grade)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...